Teladoc Health, Inc. (TDOC) Stock Analysis and Metrics

Teladoc Health

NYSE: TDOC

$8.77 ▲ +0.11 (+1.33%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.55 Bn

P/E-9.06

P/S0.62

Div. Yield0.00

Revenue Growth (1y) (Qtr)-2.47

Add ratio to table…

About

Teladoc Health is a global leader in virtual care providing telehealth visits integrated care and mental health services through its platforms. The company generates revenue primarily from access fees paid by employers health plans and other clients on a per member per month basis supplemented by visit fees and sales of hardware and related services to hospitals and health systems. The company operates through the following segments: Integrated Care and BetterHelp. •…

Investment Thesis

▲ Bull case

Teladoc Health’s Integrated Care segment is positioned for a revenue inflection point as the shift from subscription-based to visit-based arrangements transitions from a headwind to a tailwind later in 2026. Management noted that while the mix shift created near-term pressure, exit 2026 will see approximately 70% of membership in visit-based models compared to 30% a few years ago, and with the launch of the enhanced 24/7 care offering—featuring specialist support, real-time prescription checks, and expanded in-network connections—multiple health plans have already adopted the service, with expectations of broader adoption. This evolution allows Teladoc to capture higher value per interaction, improve clinical outcomes, and deepen client retention, particularly as chronic care demand grows due to rising prevalence of multi-condition bundles and client preference for integrated solutions over fragmented point solutions. The company’s investments in Pulse Intelligence and Prism platforms are turning data into actionable insights, enabling AI-driven care coordination that enhances provider efficiency and patient engagement. These innovations, combined with Teladoc’s national scale and trusted relationships, create a defensible moat in virtual-first care that is difficult for niche competitors to replicate, especially as health plans seek to consolidate vendors and reduce administrative complexity. The moderation of revenue headwinds and emergence of a net tailwind by year-end positions Integrated Care for accelerating growth in the second half of 2026 and into 2027, supported by strong visit revenue growth and international expansion in hybrid care models, which saw 30% year-over-year growth in Q1.
BetterHelp’s insurance rollout is emerging as a powerful and underappreciated catalyst for sustainable U.S. growth, with early metrics showing insurance-covered users averaging 20% more sessions than cash-pay users in their first 90 days and markets where insurance launched by 2025 showing nearly an 800 basis point improvement in revenue performance versus cash-pay-only markets. The integration of Uplift is progressing ahead of expectations, with operations live in 30 states and D.C., over 6,000 providers credentialed, and insurance-covered lives grown to 150 million—a 30 million increase since year-end 2025. BetterHelp’s insurance-covered sessions now exceed 14,000 per week, translating to an annualized revenue run rate of over $75 million, with guidance calling for an exit 2026 run rate of $125 million or more. This trajectory is supported by stronger funnel conversion when users enter insurance information during onboarding, indicating improved activation and retention in a business that previously struggled with high drop-off due to cost barriers. Internationally, localized country launches from 2025 are delivering solid end-market growth with favorable customer acquisition costs, and plans to expand into one to two new markets in 2026 further diversify revenue streams. Crucially, management explicitly stated they do not plan to discontinue the direct-to-consumer channel, preserving brand reach and market positioning while insurance scales—a balanced approach that captures both immediate demand and long-term durability. As insurance revenue continues to grow and begins to surpass cash-pay revenue in the U.S., BetterHelp is transitioning from a volatile, ad-dependent model to a more stable, insurance-backed recurring revenue engine with higher lifetime value per user.
Teladoc’s financial discipline and capital allocation strategy are creating a foundation for long-term value creation that the market is underestimating, particularly through proactive debt management and sustained cost optimization. The company intends to address its 2027 convertible notes in two phases: first, by paying down a substantial portion with available cash and securing new traditional term debt before year-end, then paying off the remainder with cash at maturity in 2027. This approach reduces gross debt exposure while maintaining financial flexibility, supported by a net debt to trailing adjusted EBITDA ratio under 0.9x and $751 million in cash and cash equivalents at quarter-end. Simultaneously, Teladoc is driving operating leverage through AI-enabled efficiencies—such as BetterHelp’s AI-assisted clinical documentation, which has generated over 300,000 notes, saved over 4 million minutes of therapist time, and reduced administrative burden—allowing clinicians to focus on care delivery. These initiatives contribute to margin expansion, with Integrated Care’s adjusted EBITDA margin expected to improve by 45 basis points year-over-year at the midpoint of guidance, driven by cost savings offsetting mix-related pressures. The company also reduced stock-based compensation guidance to below $55 million for 2026, representing a decline of over 30% from 2025 and over 70% since 2023, signaling commitment to restraint. With free cash flow guidance of $130 million to $170 million and a focus on financial strength, Teladoc is building resilience against macroeconomic volatility while investing in innovation—such as upcoming AI-powered comprehensive care products—that could unlock new growth vectors. This combination of balance sheet strength, operational discipline, and strategic reinvestment positions the company to generate sustainable shareholder value beyond near-term earnings fluctuations.

Teladoc Health’s Integrated Care segment is positioned for a revenue inflection point as the shift from subscription-based to visit-based arrangements transitions from a headwind to a tailwind later in 2026. Management noted that while the mix shift created near-term pressure, exit 2026 will see approximately 70% of membership in visit-based models compared to 30% a few years ago, and with the launch of the enhanced 24/7 care offering—featuring specialist support, real-time prescription checks, and expanded in-network connections—multiple health plans have already adopted the service, with expectations of broader adoption. This evolution allows Teladoc to capture higher value per interaction, improve clinical outcomes, and deepen client retention, particularly as chronic care demand grows due to rising prevalence of multi-condition bundles and client preference for integrated solutions over fragmented point solutions. The company’s investments in Pulse Intelligence and Prism platforms are turning data into actionable insights, enabling AI-driven care coordination that enhances provider efficiency and patient engagement. These innovations, combined with Teladoc’s national scale and trusted relationships, create a defensible moat in virtual-first care that is difficult for niche competitors to replicate, especially as health plans seek to consolidate vendors and reduce administrative complexity. The moderation of revenue headwinds and emergence of a net tailwind by year-end positions Integrated Care for accelerating growth in the second half of 2026 and into 2027, supported by strong visit revenue growth and international expansion in hybrid care models, which saw 30% year-over-year growth in Q1.
BetterHelp’s insurance rollout is emerging as a powerful and underappreciated catalyst for sustainable U.S. growth, with early metrics showing insurance-covered users averaging 20% more sessions than cash-pay users in their first 90 days and markets where insurance launched by 2025 showing nearly an 800 basis point improvement in revenue performance versus cash-pay-only markets. The integration of Uplift is progressing ahead of expectations, with operations live in 30 states and D.C., over 6,000 providers credentialed, and insurance-covered lives grown to 150 million—a 30 million increase since year-end 2025. BetterHelp’s insurance-covered sessions now exceed 14,000 per week, translating to an annualized revenue run rate of over $75 million, with guidance calling for an exit 2026 run rate of $125 million or more. This trajectory is supported by stronger funnel conversion when users enter insurance information during onboarding, indicating improved activation and retention in a business that previously struggled with high drop-off due to cost barriers. Internationally, localized country launches from 2025 are delivering solid end-market growth with favorable customer acquisition costs, and plans to expand into one to two new markets in 2026 further diversify revenue streams. Crucially, management explicitly stated they do not plan to discontinue the direct-to-consumer channel, preserving brand reach and market positioning while insurance scales—a balanced approach that captures both immediate demand and long-term durability. As insurance revenue continues to grow and begins to surpass cash-pay revenue in the U.S., BetterHelp is transitioning from a volatile, ad-dependent model to a more stable, insurance-backed recurring revenue engine with higher lifetime value per user.
Teladoc’s financial discipline and capital allocation strategy are creating a foundation for long-term value creation that the market is underestimating, particularly through proactive debt management and sustained cost optimization. The company intends to address its 2027 convertible notes in two phases: first, by paying down a substantial portion with available cash and securing new traditional term debt before year-end, then paying off the remainder with cash at maturity in 2027. This approach reduces gross debt exposure while maintaining financial flexibility, supported by a net debt to trailing adjusted EBITDA ratio under 0.9x and $751 million in cash and cash equivalents at quarter-end. Simultaneously, Teladoc is driving operating leverage through AI-enabled efficiencies—such as BetterHelp’s AI-assisted clinical documentation, which has generated over 300,000 notes, saved over 4 million minutes of therapist time, and reduced administrative burden—allowing clinicians to focus on care delivery. These initiatives contribute to margin expansion, with Integrated Care’s adjusted EBITDA margin expected to improve by 45 basis points year-over-year at the midpoint of guidance, driven by cost savings offsetting mix-related pressures. The company also reduced stock-based compensation guidance to below $55 million for 2026, representing a decline of over 30% from 2025 and over 70% since 2023, signaling commitment to restraint. With free cash flow guidance of $130 million to $170 million and a focus on financial strength, Teladoc is building resilience against macroeconomic volatility while investing in innovation—such as upcoming AI-powered comprehensive care products—that could unlock new growth vectors. This combination of balance sheet strength, operational discipline, and strategic reinvestment positions the company to generate sustainable shareholder value beyond near-term earnings fluctuations.

▼ Bear case

Teladoc Health faces persistent structural challenges in its BetterHelp U.S. direct-to-consumer business that management is not adequately addressing, despite optimistic framing around insurance rollout progress. BetterHelp’s Q1 revenue declined 9% year-over-year, driven by a mid-teens decline in U.S. average paying users, which fell to 361,000—a trend reflecting deepening pressure on the cash-pay model due to macroeconomic headwinds, consumer discretionary spending shifts, and increased competition from lower-cost therapy apps and employer-sponsored mental health benefits. While management highlights insurance as a stabilizing force, the transition remains incomplete, with insurance-based revenue contributing only $13 million in Q1—just 6% of BetterHelp’s total revenue—and the business still reliant on volatile advertising spend, which, although down 12% year-over-year, remains a critical lever for user acquisition. The company’s expectation of exit 2026 insurance revenue run rate of $125 million or more implies that even at full ramp, insurance would cover less than half of BetterHelp’s current revenue base, leaving a significant gap to be filled by either continued cash-pay decline or unproven international growth. Furthermore, the claim that insurance-covered users have 20% more sessions than cash-pay users in the first 90 days may reflect selection bias—users who opt into insurance are likely more engaged or have higher clinical needs—rather than a causal effect of coverage, and the 800 basis point revenue improvement in early insurance markets could be driven by low baselines rather than sustainable momentum. Without a clear path to profitability in the core U.S. DTC business, BetterHelp remains a drag on consolidated results, and its long-term viability depends on successfully shifting mix toward insurance before cash-pay erosion accelerates.
The Integrated Care segment’s growth prospects are overstated, as the anticipated tailwind from the subscription-to-visit shift is contingent on uncertain health plan adoption and visit utilization trends that may not materialize as expected. Management’s assumption that visit-based revenue growth will offset subscription declines by year-end relies on the success of the enhanced 24/7 care offering and new AI-powered products, yet there is limited evidence of widespread reimbursement reform or increased utilization to support this transition. Chronic care program enrollment grew only 4% year-over-year in Q1, and while multi-condition bundles are gaining traction, the segment remains vulnerable to client consolidation efforts—health plans and employers are actively seeking to reduce vendor count and replace point solutions with integrated platforms, which could favor larger, more entrenched competitors or specialized niche players with deeper clinical integration in specific disease states. International revenue, though growing double digits, remains a small fraction of total Integrated Care revenue and is exposed to currency fluctuations, regulatory heterogeneity, and uneven adoption of virtual care models outside the U.S. The company’s reliance on product innovation to drive differentiation carries execution risk, particularly in a crowded market where AI-enabled care tools are being rapidly adopted by rivals, and Teladoc’s ability to monetize AI through outcomes-based pricing remains unproven. Moreover, the guidance for full-year Integrated Care revenue growth of 0.8% to 3.5%—with only 65 basis points from acquisitions and 60 basis points from FX—implies organic constant-currency growth of nearly zero, suggesting the core business is stagnant despite costly investments in Pulse Intelligence, Prism, and new product development.
Teladoc’s financial position, while appearing strong on the surface, is vulnerable to refinancing risks and execution-dependent cash flow generation that could undermine shareholder value if initiatives fail to deliver. Although net debt to adjusted EBITDA is under 0.9x, the company’s plan to refinance its 2027 convertible notes hinges on securing new traditional term debt before year-end—a strategy exposed to interest rate volatility and credit market conditions, particularly if Teladoc’s profitability does not improve as expected. Free cash flow guidance of $130 million to $170 million for 2026 assumes consistent performance, yet Q1 free cash flow was a $26 million outflow, and historical seasonality means the full-year outlook depends heavily on stronger second-half conversion—a risky assumption if visit revenue growth lags or cost savings initiatives fall short. The company’s adjusted EBITDA margin guidance for Integrated Care (15.1% to 16.1%) relies on ongoing cost savings offsetting mix-related gross margin pressure, but there is no clear evidence of sustainable structural cost advantages, and ongoing investments in AI, product innovation, and insurance rollout for BetterHelp continue to pressure margins. Furthermore, the expectation of declining stock-based compensation below $55 million assumes continued restraint, yet any reversal—driven by retention concerns or competitive hiring—could quickly erode profitability. With a net loss per share guidance range of $1.05 to $0.75, Teladoc remains unprofitable on a GAAP basis, and its market valuation is increasingly sensitive to interest rates and growth expectations; any failure to hit the upper end of its ranges could trigger multiple compression, especially if investors lose confidence in the turnaround narrative for BetterHelp or the scalability of AI-driven innovation in Integrated Care.

Teladoc Health faces persistent structural challenges in its BetterHelp U.S. direct-to-consumer business that management is not adequately addressing, despite optimistic framing around insurance rollout progress. BetterHelp’s Q1 revenue declined 9% year-over-year, driven by a mid-teens decline in U.S. average paying users, which fell to 361,000—a trend reflecting deepening pressure on the cash-pay model due to macroeconomic headwinds, consumer discretionary spending shifts, and increased competition from lower-cost therapy apps and employer-sponsored mental health benefits. While management highlights insurance as a stabilizing force, the transition remains incomplete, with insurance-based revenue contributing only $13 million in Q1—just 6% of BetterHelp’s total revenue—and the business still reliant on volatile advertising spend, which, although down 12% year-over-year, remains a critical lever for user acquisition. The company’s expectation of exit 2026 insurance revenue run rate of $125 million or more implies that even at full ramp, insurance would cover less than half of BetterHelp’s current revenue base, leaving a significant gap to be filled by either continued cash-pay decline or unproven international growth. Furthermore, the claim that insurance-covered users have 20% more sessions than cash-pay users in the first 90 days may reflect selection bias—users who opt into insurance are likely more engaged or have higher clinical needs—rather than a causal effect of coverage, and the 800 basis point revenue improvement in early insurance markets could be driven by low baselines rather than sustainable momentum. Without a clear path to profitability in the core U.S. DTC business, BetterHelp remains a drag on consolidated results, and its long-term viability depends on successfully shifting mix toward insurance before cash-pay erosion accelerates.
The Integrated Care segment’s growth prospects are overstated, as the anticipated tailwind from the subscription-to-visit shift is contingent on uncertain health plan adoption and visit utilization trends that may not materialize as expected. Management’s assumption that visit-based revenue growth will offset subscription declines by year-end relies on the success of the enhanced 24/7 care offering and new AI-powered products, yet there is limited evidence of widespread reimbursement reform or increased utilization to support this transition. Chronic care program enrollment grew only 4% year-over-year in Q1, and while multi-condition bundles are gaining traction, the segment remains vulnerable to client consolidation efforts—health plans and employers are actively seeking to reduce vendor count and replace point solutions with integrated platforms, which could favor larger, more entrenched competitors or specialized niche players with deeper clinical integration in specific disease states. International revenue, though growing double digits, remains a small fraction of total Integrated Care revenue and is exposed to currency fluctuations, regulatory heterogeneity, and uneven adoption of virtual care models outside the U.S. The company’s reliance on product innovation to drive differentiation carries execution risk, particularly in a crowded market where AI-enabled care tools are being rapidly adopted by rivals, and Teladoc’s ability to monetize AI through outcomes-based pricing remains unproven. Moreover, the guidance for full-year Integrated Care revenue growth of 0.8% to 3.5%—with only 65 basis points from acquisitions and 60 basis points from FX—implies organic constant-currency growth of nearly zero, suggesting the core business is stagnant despite costly investments in Pulse Intelligence, Prism, and new product development.
Teladoc’s financial position, while appearing strong on the surface, is vulnerable to refinancing risks and execution-dependent cash flow generation that could undermine shareholder value if initiatives fail to deliver. Although net debt to adjusted EBITDA is under 0.9x, the company’s plan to refinance its 2027 convertible notes hinges on securing new traditional term debt before year-end—a strategy exposed to interest rate volatility and credit market conditions, particularly if Teladoc’s profitability does not improve as expected. Free cash flow guidance of $130 million to $170 million for 2026 assumes consistent performance, yet Q1 free cash flow was a $26 million outflow, and historical seasonality means the full-year outlook depends heavily on stronger second-half conversion—a risky assumption if visit revenue growth lags or cost savings initiatives fall short. The company’s adjusted EBITDA margin guidance for Integrated Care (15.1% to 16.1%) relies on ongoing cost savings offsetting mix-related gross margin pressure, but there is no clear evidence of sustainable structural cost advantages, and ongoing investments in AI, product innovation, and insurance rollout for BetterHelp continue to pressure margins. Furthermore, the expectation of declining stock-based compensation below $55 million assumes continued restraint, yet any reversal—driven by retention concerns or competitive hiring—could quickly erode profitability. With a net loss per share guidance range of $1.05 to $0.75, Teladoc remains unprofitable on a GAAP basis, and its market valuation is increasingly sensitive to interest rates and growth expectations; any failure to hit the upper end of its ranges could trigger multiple compression, especially if investors lose confidence in the turnaround narrative for BetterHelp or the scalability of AI-driven innovation in Integrated Care.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VEEV	Veeva Systems Inc	29.34 Bn	31.16	8.84	-
2	BTSG	BrightSpring Health Services, Inc.	13.49 Bn	46.18	0.99	2.50 Bn
3	HQY	Healthequity, Inc.	7.96 Bn	34.51	5.95	0.94 Bn
4	TXG	10x Genomics, Inc.	6.17 Bn	-272.14	9.65	-
5	HNGE	Hinge Health, Inc.	6.02 Bn	-11.77	9.31	-
6	MMED	MiniMed Group, Inc.	4.19 Bn	-8.88	1.38	-
7	WAY	Waystar Holding Corp.	4.14 Bn	32.80	3.58	1.47 Bn
8	DOCS	Doximity, Inc.	3.82 Bn	19.51	5.93	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password